ORCID as entered in ROS

Select Publications
2006, 'In reply [9]', Medical Journal of Australia, 184, pp. 44 - 45, http://dx.doi.org/10.5694/j.1326-5377.2006.tb00101.x
,2006, 'Can we deny patients expensive drugs?', Australian Prescriber, 29, pp. 146 - 148, http://dx.doi.org/10.18773/austprescr.2006.087
,2006, 'Access to high-cost medicines for the treatment of rheumatoid arthritis under Australia's pharmaceutical benefits scheme', Pharmacoepidemiology and Drug Safety, 15, pp. S213 - S213
,2006, 'Access to tumour necrosis factor inhibitors for rheumatoid arthritis treatment under the Australian Pharmaceutical Benefits Scheme: are we on target?', Internal Medicine Journal, 36, pp. 19 - 27, http://dx.doi.org/10.1111/j.1445-5994.2005.00992.x
,2006, 'Accessing health outcome data on high-cost medicines in Australia', Medical Journal of Australia, 184, pp. 411 - 413, http://dx.doi.org/10.5694/j.1326-5377.2006.tb00293.x
,2006, 'An integrated analysis of five double-blind, randomized controlled trials evaluating the safety and efficacy of a hyaluronan product for intra-articular injection in osteoarthritis of the kneel', Osteoarthritis and Cartilage, 14, pp. 859 - 866
,2006, 'Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: Effect of induction by rifampin and ethnicity', Clinical Pharmacology and Therapeutics, 80, pp. 75 - 84
,2006, 'Giving and receiving of gifts between pharmaceutical companies and medical specialists in Australia', Internal Medicine Journal, 26, pp. 571 - 578
,2006, 'Pethidine in emergency departments: promoting evidence-based prescribing - Reply', Medical Journal of Australia, 184, pp. 44 - 45
,2006, 'Protocol for the Quick Clinical study - a randomised controlled trial to assess the impact of an online evidence retrieval system on decision-making in general practice', BMC Medical Informatics and Decision Making, 6
,2006, 'Response to expression of concern regarding VIGOR study', New England Journal of Medicine, 354, pp. 1196 - 1198
,2006, 'Utilisation of anti-rheumatic drugs in Australia: Impact of introducing high-cost biologics under the pharmaceutical benefits scheme', Pharmacoepidemiology and Drug Safety, 15, pp. S213 - S213
,2005, 'Perspectives on Drug and Therapeutics Committee policy implementation', Research in Social and Administrative Pharmacy, 1, pp. 526 - 545, http://dx.doi.org/10.1016/j.sapharm.2005.09.001
,2005, 'Evaluation of access to high-cost medicines in Australia using national claims data', VALUE IN HEALTH, 8, pp. A28 - A28, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000233021700088&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2005, 'Access to medicines and high-quality therapeutics: Global responsibilities for clinical pharmacology', Medical Journal of Australia, 182, pp. 322 - 323, http://dx.doi.org/10.5694/j.1326-5377.2005.tb06728.x
,2005, 'The birth of ibuprofen', Australian Journal of Pharmacy, 86, pp. 84 - 85
,2005, 'Challenges and Progress in adverse event ascertainment and reporting in clinical trials', Journal of Rheumatology, 32, pp. 2030 - 2032
,2005, 'Cooperative partnerships or conflict-of-interest? A national survey of interaction between the pharmaceutical industry and medical organizations', Internal Medicine Journal, 35, pp. 206 - 210
,2005, 'Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects', British Journal of Clinical Pharmacology, 59, pp. 425 - 432
,2005, 'Manipulative therapy and/or NSAIDs for acute low back pain: design of a randomized controlled trial [ACTRN012605000036617]', BMC Musculoskeletal Disorders, 6
,2005, 'Medical specialists and pharmaceutical industry-sponsored research: a survey of the Australian experience', Medical Journal of Australia, 182, pp. 557 - 560
,2005, 'Paracetamol should be first-line therapy in osteoarthritis', Medical Journal of Australia, 182, pp. 198 - 199
,2005, 'Pethidine in emergency departments: promoting evidence-based prescribing', Medical Journal of Australia, 183, pp. 129 - 133
,2005, 'Recent developments in targeting access to high cost medicines in Australia', Australia and New Zealand Health Policy, 2, pp. 1 - 8
,2005, 'Sample size is beside the point in policy development research', Australian and New Zealand Journal of Public Health, 29, pp. 583 - 583
,2005, 'Simultaneous determination of rofecoxib and celecoxib in human plasma by high-performance liquid chromatography', Journal of Chromatographic Science, 43, pp. 351 - 354
,2005, 'Standardized Assessment of adverse events in rheumatology clinical trials: Summary of the OMERACT 7 Drug Safety Module Update', Journal of Rheumatology, 32, pp. 2037 - 2041
,2005, 'Targeted access to high-cost medicines in Australia: Early analysis from a qualitative study', Value in Health, 8, pp. A28 - A28
,2005, 'Ties that bind - Multiple relationships between clinical researchers and the pharmaceutical industry', Archives of Internal Medicine, 165, pp. 2493 - 2496
,2005, 'Tolerability of paracetamol', Drug Safety, 28, pp. 227 - 240
,2004, 'Erratum: Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects (British Journal of Clinical Pharmacology (2004) 57 (592-599))', British Journal of Clinical Pharmacology, 58, pp. 102, http://dx.doi.org/10.1111/j.1365-2125.2004.02155.x
,2004, 'The vascular effects of COX-2 selective inhibitors', Australian Prescriber, 27, pp. 142 - 145, http://dx.doi.org/10.18773/austprescr.2004.119
,2004, 'A double blind, randomized, multicenter, parallel group study of the effectiveness and tolerance of intraarticular hyaluronan in osteoarthritis of the knee', Journal of Rheumatology, 31, pp. 775 - 782
,2004, 'A phase I study of the pharmacokinetics and safety of passive immunotherapy with caprine anti-HIV antibodies, (PE)HRG214, in HIV-1-infected individuals', HIV Clinical Trials, 5, pp. 91 - 98
,2004, 'Access to high cost drugs in Australia', British Medical Journal: Clinical Research, 329, pp. 415 - 416
,2004, 'Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects', British Journal of Clinical Pharmacology, 57, pp. 592 - 599
,2004, 'Pharmacokinetic-pharmacodynamic modelling to investigate herb-drug interactions with warfarin', Clinical and Experimental Pharmacology and Physiology, 31, pp. A227 - A227
,2004, 'Protocol Appraisal: A Study Site's Viewpoint', Applied Clinical Trials, 13, pp. 34 - 42
,2004, 'Stakeholder Opinions on the Implementation of Drug and Therapeutics Committee Decisions', Journal of Pharmacy Practice and Research, 34, pp. 178 - 182
,2004, 'Stereoselective disposition of ibuprofen enantiomers in man (Reprintedfrom Br J Clin Pharmacol, vol 19, pg 669-674, 1985)', British Journal of Clinical Pharmacology, 58, pp. S759 - S764
,2003, 'Tolerability of Paracetamol', Drugs, 63, pp. 43 - 46, http://dx.doi.org/10.2165/00003495-200363992-00007
,2003, 'COX-2: Where are we in 2003? Distinction from NSAIDs becoming blurred', Arthritis Research and Therapy, 5, pp. 116 - 119
,2003, 'Adverse event reporting in clinical trials: room for improvement', Medical Journal of Australia, 179, pp. 426 - 428
,2003, 'Alcohol and paracetamol', Australian Prescriber, 27, pp. 14 - 15
,2003, 'Drug and therapeutics committees - are they fulfilling their potential to improve the quality use of medicines?', International Journal of Pharmacy Practice, 11, pp. 175 - 181
,2003, 'Human subcutaneous tissue distribution of fluconazole: comparison of microdialysis and suction blister techniques', British Journal of Pharmacology, 56, pp. 551 - 561
,2003, 'Hypertension in the patient with arthritis: Have we underestimated its significance?', Journal of Rheumatology, 30, pp. 642 - 644
,2003, 'Pharmaceutical health and rational use of medicines committee', Journal of Pharmacy Practice and Research, 33, pp. 87 - 89
,2003, 'Pharmacokinetics of estradiol, progesterone, testosterone and dehydroepiandrosterone after transbuccal administration to postmenopausal women', Climacteric, 6, pp. 104 - 111
,2003, 'Tolerability of paracetamol', DRUGS, 63, pp. 43 - 46
,